Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

被引:117
|
作者
Higashihara, Eiji [2 ]
Torres, Vicente E. [1 ]
Chapman, Arlene B. [3 ]
Grantham, Jared J. [4 ]
Bae, Kyongtae [5 ]
Watnick, Terry J. [6 ]
Horie, Shigeo [7 ]
Nutahara, Kikuo [2 ]
Ouyang, John [8 ]
Krasa, Holly B. [8 ]
Czerwiec, Frank S. [8 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Coll Med, Rochester, MN 55905 USA
[2] Kyorin Univ, Sch Med, Tokyo, Japan
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Teikyo Univ, Sch Med, Tokyo 173, Japan
[8] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA
基金
美国国家卫生研究院;
关键词
DIETARY-PROTEIN RESTRICTION; BLOOD-PRESSURE CONTROL; VOLUME PROGRESSION;
D O I
10.2215/CJN.03530411
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses of primary and secondary end points included LMM using all subject data and mixed model repeated measures (MMRM) of change from baseline at each year. Pearson correlation tested the association between log-TKV and eGFR changes. Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls 1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m(2)) were similar. Control TKV increased 5.8% versus 1.7%/yr for tolvaptan (P < 0.001, estimated ratio of geometric mean 0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined: -2.1 versus -0.71 ml/min per 1.73 m(2)/yr (P = 0.01, LMM group difference 1.1 ml/min per 1.73 m(2)/yr [95% confidence interval 0.24 to 1.9]). Sensitivity analyses including withdrawn subjects were similar, whereas MMRM analyses were significant at each year for TKV and nonsignificant for eGFR. Increasing TKV correlated with decreasing eGFR (r = -0.21, P < 0.01). Conclusion ADPKD cyst growth progresses more slowly with tolvaptan than in historical controls, but AEs are common. Clin J Am Soc Nephrol 6: 2499-2507, 2011. doi: 10.2215/CJN.03530411
引用
收藏
页码:2499 / 2507
页数:9
相关论文
共 50 条
  • [1] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Spital, Aaron
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1257 - 1257
  • [2] Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
    Ingelfinger, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1988 - 1989
  • [3] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Reply
    Torres, Vicente E.
    Gansevoort, Ron T.
    Czerwiec, Frank S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1259 - 1259
  • [4] Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Baur, Brian P.
    Meaney, Calvin J.
    PHARMACOTHERAPY, 2014, 34 (06): : 605 - 616
  • [5] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Blair, Hannah A.
    DRUGS, 2019, 79 (03) : 303 - 313
  • [6] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Hannah A. Blair
    Gillian M. Keating
    Drugs, 2015, 75 : 1797 - 1806
  • [7] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Hannah A. Blair
    Drugs, 2019, 79 : 303 - 313
  • [8] Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Grantham, Jared J.
    Higashihara, Eiji
    Perrone, Ronald D.
    Krasa, Holly B.
    Ouyang, John
    Czerwiec, Frank S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (25): : 2407 - 2418
  • [9] An update on tolvaptan for autosomal dominant polycystic kidney disease
    Poch, E.
    Rodas, L.
    Blasco, M.
    Molina, A.
    Quintana, L.
    DRUGS OF TODAY, 2018, 54 (09) : 519 - 533
  • [10] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Blair, Hannah A.
    Keating, Gillian M.
    DRUGS, 2015, 75 (15) : 1797 - 1806